BDT compounds (FLT3 inhibitors)
Neuropathic Pain (and opioid-combination pain indications)
PreclinicalActive
Key Facts
Indication
Neuropathic Pain (and opioid-combination pain indications)
Phase
Preclinical
Status
Active
Company
About Biodol
Biodol Therapeutics is a preclinical-stage biotech pioneering a novel approach to chronic neuropathic pain by targeting the FLT3 receptor, a key player in pain pathophysiology. Its proprietary compounds not only reverse pain symptoms in models but also potentiate morphine and abolish opioid-induced tolerance, positioning them to address the opioid crisis. With a strong IP portfolio covering FLT3 inhibition for pain and a recent licensing deal with Kyorin Pharmaceutical, Biodol is advancing lead compounds toward clinical development in a multi-billion dollar market.
View full company profile